• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    SOLID PHARMACEUTICAL COMPOSITION,ORAL TABLET AND LIQUID PHARMACEUTICAL COMPOSITIONSUBSTANTIALLY NOT AQUEOUS. These are corticosteroid compositionsorally administered and methods of treating a condition associated with inflammation of the gastrointestinal tract in an individual, which comprisesadministering said corticosteroid composition to a subjectorally administered.
    公开号:BR112012007110A2
    申请号:R112012007110-6
    申请日:2010-09-30
    公开日:2021-08-31
    发明作者:Frederic Jay Cohen；Gopi M. Venkatesh；Stephen Perrett
    申请人:Aptalis Pharmatech, Inc.；
    IPC主号:
    专利说明:

    SOLID PHARMACEUTICAL COMPOSITION, TABLET OF ORAL DISINTEGRATION AND LIQUID PHARMACEUTICAL COMPOSITION SUBSTANTIALLY NOT AQUEOUS
    CROSS REFERENCE REGARDING RELATED ORDERS This application claims priority to Provisional Application No. US 61/247,642, filed October 1, 2009, the disclosure of which is incorporated herein by reference in its entirety. for all purposes.
    TECHNICAL FIELD OF THE INVENTIONS This invention relates to orally administered corticosteroid compositions useful for treating conditions associated with inflammation of the gastrointestinal tract.
    BACKGROUND OF THE INVENTION There are currently no approved topically administered anti-inflammatory medications for the treatment of conditions associated with inflammation of the upper gastrointestinal tract. Such a condition, eosinophilic esophagitis (EE), is an inflammatory condition of the esophagus. It is histologically characterized by the proliferation of eosinophils. The disease is painful, leads to difficulty in swallowing and predisposes patients to food impaction and other complications. Experimental and "off-label" treatments for EE include directing formulated and approved inhalation steroid medications to the back of the throat so that they are not appreciably inhaled, and instructing the patient to rinse their mouth immediately after administration and do not swallow food or water for two hours after administration. Rinsing is recommended because the
    权利要求:
    Claims (30)
    [1]
    1. SOLID PHARMACEUTICAL COMPOSITION, characterized in that it comprises less than or equal to 20 mg of a corticosteroid, wherein the composition has no significant systemic glucocorticoid or mineralocorticoid activity following oral administration, wherein the solid pharmaceutical composition disintegrates within 60 seconds in simulated saliva fluid when tested using the USP <701> Disintegration Test.
    [2]
    2. SOLID PHARMACEUTICAL COMPOSITION, according to claim 1, characterized in that said solid pharmaceutical composition disintegrates in 30 seconds.
    [3]
    SOLID PHARMACEUTICAL COMPOSITION according to claim 1, wherein said corticosteroid is selected from the group consisting of budesonide, fluticasone, flunisolide, ciclesonide, mometasone, beclomethasone, and salts, solvates and esters thereof.
    [4]
    4. SOLID PHARMACEUTICAL COMPOSITION, according to claim 1, characterized in that it further comprises an adhesive agent.
    [5]
    A SOLID PHARMACEUTICAL COMPOSITION according to claim 1, characterized in that it comprises a disintegrant selected from the group consisting of crospovidone, sodium starch glycollate, cross-linked carboxymethyl cellulose, low-substituted hydroxylpropyl cellulose, mannitol, xylitol, sorbitol, mal tol, maltitol, lactose, sucrose, maltose, and combinations thereof.
    [6]
    6. SOLID PHARMACEUTICAL COMPOSITION according to claim 1, characterized in that it further comprises an excipient selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, cyclodextrin, and combinations thereof.
    [7]
    A SOLID PHARMACEUTICAL COMPOSITION according to claim 1, characterized in that it is substantially free of lubricant.
    [8]
    PHARMACEUTICAL COMPOSITION, according to claim 1', characterized in that the pharmaceutical composition is in the form of an orally disintegrating tablet (ODT).
    [9]
    A PHARMACEUTICAL COMPOSITION according to claim 8, wherein the ODT comprises drug particles and fast-dispersing granules, wherein the drug particles comprise the corticosteroid, and the fast-dispersing granules comprise a disintegrant and an alcohol of sugar and/or saccharide.
    [10]
    A PHARMACEUTICAL COMPOSITION according to claim 9, wherein the drug particles have an average particle size of less than about 400 µm, the rapidly dispersing granules have an average particle size of less than about 300 µm. pm, and the disintegrant and sugar and/or saccharide alcohol have an average particle size of less than about 30 pm.
    [11]
    11. A PHARMACEUTICAL COMPOSITION according to claim 9, characterized in that the corticosteroid is disposed on the surface of an excipient, the rapidly dispersing granules have an average particle size of less than about 300 µm, and the disintegrant and sugar alcohol and/or saccharide have an average particle size of less than about 30 µm.
    [12]
    12. PHARMACEUTICAL COMPOSITION according to claim 4, characterized in that the adhesive agent and the corticosteroid are closely associated.
    [13]
    13. PHARMACEUTICAL COMPOSITION according to claim 9, characterized in that the ODT comprises a lyophilized matrix, wherein the lyophilized matrix comprises the corticosteroid in combination with at least one excipient.
    [14]
    A PHARMACEUTICAL COMPOSITION according to claim 13, characterized in that the excipient is selected from the group consisting of mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose and combinations thereof.
    [15]
    15. ORAL DISINTEGRATION TABLET, characterized in that it comprises less than or equal to 20 mg of a corticosteroid selected from the group consisting of fluticasone, budesonide, mometasone, and salts, solvates and esters thereof, wherein the tablet of Oral disintegration disintegrates in 60 seconds in simulated sal iva fluid when tested using the USP Disintegration Test <701>.
    [16]
    The orally disintegrating tablet of claim 15, wherein the orally disintegrating tablet comprises about 0.05 to 0.3 mg of fluticasone.
    [17]
    A PHARMACEUTICAL COMPOSITION according to claim 1, characterized in that it treats an inflammatory condition of the gastrointestinal tract.
    [18]
    A PHARMACEUTICAL COMPOSITION according to claim 17, characterized in that said inflammation of the gastrointestinal tract comprises inflammation of the esophagus.
    [19]
    19. PHARMACEUTICAL COMPOSITION according to claim 17, characterized in that said condition is eosinophilic esophagitis.
    [20]
    20. PHARMACEUTICAL COMPOSITION according to claim 17, characterized in that said inflammation comprises inflammation of the glottis, epiglottis, tonsil or oropharynx.
    [21]
    21. A SUBSTANTIALLY NON-AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION, characterized in that it comprises a corticosteroid and a pharmaceutically acceptable liquid.
    [22]
    A LIQUID PHARMACEUTICAL COMPOSITION according to claim 21, wherein the liquid is selected from the group consisting of pharmaceutically acceptable alcohols, oils, glycols, ether glycols, pyrrolidones, polyethylene glycols, N-methyl-2-pyrrolidone , 2-5 pyrrolidone, glycerol, tetraglycol, glycerol formal, solketal, ethyl acetate, ethyl lactate, ethyl butyrate, dibutyl malonate, tributyl citrate, tri-n-hexyl acetyl citrate, diethyl succinate, diethyl glutarate , diethyl malonate, triethyl citrate, triacetin, tributyrin, diethyl carbonate, propylene carbonate, acetone, methyl ethyl ketone, dimethyl sulfoxide, dimethyl sulfone, tetrahydrofuran, caprolactam, N,N-diethyl-m-toluamide, 1-dodecylazacycloheptan -2-one, 1,3-dimethyl-3,4,5,6-tetrohydro-2(1H)-pyrimidinone, and combinations thereof.
    [23]
    A LIQUID PHARMACEUTICAL COMPOSITION according to claim 21, further comprising a phase change agent dissolved or suspended in said liquid, wherein upon administration to a patient, said composition undergoes a change in phase. physical properties of the composition upon contact with said patient's gastrointestinal tract, whereby contact of the corticosteroid with the patient's gastrointestinal tract is enhanced and/or prolonged.
    [24]
    24. LIQUID PHARMACEUTICAL COMPOSITION, according to claim 23, characterized in that after administration to a patient, said composition precipitates on the mucosa of the gastrointestinal tract of the patient, whereby the deposition of the corticosteroid on the mucosa of the gastrointestinal tract is intensified and/or prolonged.
    [25]
    25. LIQUID PHARMACEUTICAL COMPOSITION, according to claim 23, characterized in that after administration to a patient, said composition forms a gel in contact with the mucosa of the patient's gastrointestinal tract, through which the deposition of the corticosteroid on the mucosa of the gastrointestinal tract is intensified and/or prolonged.
    [26]
    26. LIQUID PHARMACEUTICAL COMPOSITION, according to claim 21, characterized in that after administration to a patient, said composition increases in viscosity upon contact with the mucosa of the patient's gastrointestinal tract, whereby the residence time of the corticosteroid in the intestinal tract mucosa is prolonged.
    [27]
    LIQUID PHARMACEUTICAL COMPOSITION according to claim 23, characterized in that the phase change agent is a polymer selected from the group consisting of poly(N-isopropylacrylamide), poly(ethylene glycol-(DL-lactic acid) -co-glycolic acid)-ethylene glycol) and mixtures thereof.
    [28]
    A PHARMACEUTICAL COMPOSITION according to claim 21, wherein said corticosteroid is selected from the group consisting of budesonide, fluticasone, flunisolide, ciclesonide, mometasone, tixocortol, beclomethasone, and salts, solvates and esters thereof.
    [29]
    A PHARMACEUTICAL COMPOSITION according to claim 25, characterized in that said liquid is water miscible and said phase change agent is a biogelling polymer which has a low water solubility.
    [30]
    A PHARMACEUTICAL COMPOSITION as claimed in claim 23, wherein said phase change agent increases in viscosity when in contact with oropharyngeal fluids, and wherein said increase in viscosity is at least 50%.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112012007110A2|2021-08-31|Solid pharmaceutical composition, orally disintegrating tablet and substantially non-aqueous liquid pharmaceutical composition
    JP2013506683A5|2013-11-07|
    JP2018135382A|2018-08-30|Corticosteroid compositions
    KR101329496B1|2013-11-13|Transmucosal delivery devices with enhanced uptake
    US20210275438A1|2021-09-09|Methods of treating eosinophilic esophagitis
    TWI536997B|2016-06-11|Andrographis paniculata extract
    RU2681930C2|2019-03-14|Application of andrographolide in preparation of pharmaceutical drug for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof
    JP2019528272A5|2020-09-03|
    JP2020526579A|2020-08-31|Isotretinoin oral mucosal preparation and its usage
    EP2767282B1|2020-04-15|Use of glutaryl histamine to treat respiratory tract infections
    ES2315479T3|2009-04-01|USE OF SUCH GLYCOSAMINOGLYCANS AS P.E.HEPARINA FOR THE TREATMENT OF RESPIRATORY DISORDERS SUCH AS COPD.
    CN104736142B|2020-03-03|Apixaban liquid formulations
    TW201201816A|2012-01-16|Hypersulfated glucopyranosides
    CN105997949B|2019-04-09|A kind of bulleyaconitine A orodispersible film preparation and its preparation process
    EP2997969A1|2016-03-23|Treatment agent and treatment method for intestinal examination or surgery
    CN105079012B|2018-09-28|Application of the Gastrodin in the drug or food for preparing prevention ulcerative colitis
    CN105147703B|2018-06-08|Application of the obakunone in the drug for preparing prevention ulcerative colitis
    JP2022505535A|2022-01-14|Mucosal adhesive pharmaceutical composition of corticosteroids
    Gunnarsson1999|Local corticosteroid treatment of caustic injuries of the esophagus: a preliminary report
    EP3741368A1|2020-11-25|Capsule for treating ulcerative colitis
    Chaudhari et al.2018|Mouth dissolving strips–a review
    Rao et al.2015|Design and in Vitro Evaluation Studies of Tramadol Hydrochloride Lozenzes for Treatment of Pain in Childreans
    JP2010150242A|2010-07-08|Oral medical composition containing amlexanox and ephedrines
    CN105412106A|2016-03-23|Composition containing montelukast and desloratadine and preparation method thereof
    同族专利:
    公开号 | 公开日
    EP2845595A1|2015-03-11|
    DK2482822T3|2018-08-27|
    ES2683864T3|2018-09-28|
    TWI562779B|2016-12-21|
    JP6293230B2|2018-03-14|
    EP3403654A1|2018-11-21|
    US20180153802A1|2018-06-07|
    US11246828B2|2022-02-15|
    CO6531427A2|2012-09-28|
    IL238915D0|2015-06-30|
    MY171317A|2019-10-08|
    IL218928D0|2012-07-31|
    MX2012003823A|2012-07-30|
    KR20150043548A|2015-04-22|
    JP2013506683A|2013-02-28|
    US20210244660A1|2021-08-12|
    CA2776164C|2016-12-13|
    ZA201301380B|2014-07-30|
    UA108360C2|2015-04-27|
    PL3403654T3|2019-11-29|
    JP2015096540A|2015-05-21|
    NZ599401A|2014-09-26|
    EA031157B1|2018-11-30|
    KR20140088236A|2014-07-09|
    CA2940931A1|2011-04-07|
    PT3403654T|2019-09-05|
    WO2011041509A1|2011-04-07|
    US8771729B2|2014-07-08|
    CN107252488A|2017-10-17|
    JP2018100286A|2018-06-28|
    US20110081411A1|2011-04-07|
    SG10201405886WA|2014-11-27|
    TW201117815A|2011-06-01|
    EP3403654B1|2019-07-31|
    TW201521732A|2015-06-16|
    IL238915A|2017-06-29|
    US20200214979A1|2020-07-09|
    US10632069B2|2020-04-28|
    KR20120104975A|2012-09-24|
    AU2010300550B2|2014-10-30|
    US20170071855A1|2017-03-16|
    SG10201912526TA|2020-02-27|
    EA031157B9|2019-01-31|
    TWI594754B|2017-08-11|
    US9387167B2|2016-07-12|
    RS59241B1|2019-10-31|
    CA2776164A1|2011-04-07|
    RS57595B1|2018-11-30|
    EA201290171A1|2012-11-30|
    US9849084B2|2017-12-26|
    EA201491358A1|2015-03-31|
    JP2020097625A|2020-06-25|
    AU2010300550A1|2012-04-12|
    EP2482822B1|2018-08-01|
    HUE040119T2|2019-02-28|
    DK3403654T3|2019-08-26|
    US9486407B2|2016-11-08|
    NZ624922A|2016-05-27|
    LT3403654T|2019-09-10|
    GEP20156281B|2015-05-11|
    JP6249935B2|2017-12-20|
    DE202010018594U1|2018-02-16|
    US11266598B2|2022-03-08|
    ZA201202208B|2014-11-26|
    SI3403654T1|2019-10-30|
    UY32925A|2011-04-29|
    US20140287051A1|2014-09-25|
    UA118087C2|2018-11-26|
    AR078499A1|2011-11-09|
    HRP20181266T1|2018-10-05|
    CN102665722A|2012-09-12|
    HRP20191435T1|2019-11-15|
    SI2482822T1|2018-10-30|
    EP2482822A4|2014-03-12|
    HUE046748T2|2020-03-30|
    CA2940931C|2019-04-30|
    IL218928A|2016-10-31|
    CN106421797A|2017-02-22|
    SG10201704847WA|2017-07-28|
    MX364947B|2019-05-15|
    CL2012000794A1|2012-07-20|
    EP2482822A1|2012-08-08|
    ME03471B|2020-01-20|
    JP2017036306A|2017-02-16|
    CA3037273A1|2011-04-07|
    US20140303131A1|2014-10-09|
    LT2482822T|2018-09-10|
    ES2742525T3|2020-02-14|
    EA024084B1|2016-08-31|
    PL2482822T3|2018-10-31|
    MX2019005289A|2019-08-05|
    EP3760187A1|2021-01-06|
    PT2482822T|2018-10-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1170188A|1967-09-15|1969-11-12|Bayer Ag|N-trityl-imidazoles and salts and uses thereof|
    SE378109B|1972-05-19|1975-08-18|Bofors Ab|
    DE2260384C3|1972-12-09|1979-11-29|Hoechst Ag, 6000 Frankfurt|Oral corticosteroid preparation|
    US4080448A|1974-11-13|1978-03-21|Mirsky Louis H|Method of treating cellular stress|
    PH24267A|1980-02-15|1990-05-29|Glaxo Group Ltd|Androstane carbothioates and pharmaceutical compositions containing the same|
    SE8004580L|1980-06-19|1981-12-20|Draco Ab|PHARMACEUTICAL PREPARATION|
    EP0057401B1|1981-02-02|1984-08-01|Schering Corporation|Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them|
    GB8630913D0|1986-12-24|1987-02-04|Glaxo Group Ltd|Pharmaceutical compositions|
    ZA892859B|1988-04-22|1989-12-27|Advanced Polymer Systems Inc|Porous particles in preparations involving immiscible phases|
    US5278175A|1990-02-02|1994-01-11|Pfizer Inc.|Triazole antifungal agents|
    GB9002375D0|1990-02-02|1990-04-04|Pfizer Ltd|Triazole antifungal agents|
    GR1001529B|1990-09-07|1994-03-31|Elmuquimica Farm Sl|Process for the obtainment of a new pregna-1,4-diene-3,20-dione -16-17-acetal-21 esters|
    CA2101773A1|1991-01-31|1992-08-01|Toyoichi Tanaka|Interpenetrating-polymer network phase-transition gels|
    US5446070A|1991-02-27|1995-08-29|Nover Pharmaceuticals, Inc.|Compositions and methods for topical administration of pharmaceutically active agents|
    US5252337A|1991-06-25|1993-10-12|Eurand America, Inc.|Controlled release calcium channel blocker microcapsules|
    NZ276637A|1993-12-20|1997-07-27|Minnesota Mining & Mfg|Aerosol containing flunisolide, ethanol, and tetrafluoroethane and/or heptafluoropropane propellant|
    US5639475A|1995-02-03|1997-06-17|Eurand America, Incorporated|Effervescent microcapsules|
    SE9501384D0|1995-04-13|1995-04-13|Astra Ab|Process for the preparation of respirable particles|
    GB9517062D0|1995-08-18|1995-10-25|Scherer Ltd R P|Pharmaceutical compositions|
    DE19606151C2|1996-02-20|1999-05-12|Losan Pharma Gmbh|Effervescent ibuprofen preparation and process for making the same|
    US8071128B2|1996-06-14|2011-12-06|Kyowa Hakko Kirin Co., Ltd.|Intrabuccally rapidly disintegrating tablet and a production method of the tablets|
    ES2243998T3|1996-06-14|2005-12-01|Kyowa Hakko Kogyo Co., Ltd.|COMPRESSED QUICK DISGREGATION VIA INTRABUCAL.|
    NZ334914A|1996-10-01|2000-09-29|Stanford Res Inst Int|Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique|
    SE9604486D0|1996-12-05|1996-12-05|Astra Ab|Novel formulation|
    GB9707934D0|1997-04-18|1997-06-04|Danbiosyst Uk|Improved delivery of drugs to mucosal surfaces|
    IT1291362B1|1997-05-13|1999-01-07|Vectorpharma Int|BIPHASIC MULTICOMPONENT PHARMACEUTICAL COMPOSITIONS CONTAINING SUBSTANCES SUITABLE TO MODIFY THE PARTITION OF THE ACTIVE SUBSTANCES|
    RO118174B1|1997-08-21|2003-03-28|Aventis Pharma Deutschland Gmbh|Nail polish and use thereof|
    GB9722426D0|1997-10-23|1997-12-24|Univ London Pharmacy|Controlled release formulations|
    PT1058538E|1998-03-06|2002-11-29|Eurand Int|TABLETS FOR FAST DISINTEGRATION|
    FR2781156B1|1998-07-20|2001-06-29|Lafon Labor|PHARMACEUTICAL COMPOSITION FOR PARTICULARLY FOR THE PREVENTION AND TREATMENT OF RADIOMUCITES AND CHEMOMUCITES|
    US6596298B2|1998-09-25|2003-07-22|Warner-Lambert Company|Fast dissolving orally comsumable films|
    US6863378B2|1998-10-16|2005-03-08|Silverbrook Research Pty Ltd|Inkjet printer having enclosed actuators|
    LT2915534T|1999-04-23|2018-06-25|Leo Pharma A/S|Pharmaceutical composition for dermal use to treat psoriasis comprising a vitamin D and a corticosteroid|
    GB9915319D0|1999-06-30|1999-09-01|Unilever Plc|Hair treatment compositions|
    IT1317904B1|1999-09-11|2003-07-15|Glaxo Group Ltd|PHARMACEUTICAL FORMULATION OF FLUTICASONE PROPIONATE.|
    KR100446101B1|2000-12-07|2004-08-30|주식회사 삼양사|Sustained delivery composition for poorly water soluble drugs|
    US7125564B2|2001-02-16|2006-10-24|Lavipharm Laboratories, Inc.|Water soluble and palatable complexes|
    US20030050312A1|2001-03-12|2003-03-13|Hjorth Thyge Borup|Novel tablets and capsules and a process for its preparation|
    WO2002072150A2|2001-03-13|2002-09-19|Angiotech Pharmaceuticals Inc.|Micellar drug delivery vehicles and uses thereof|
    AT333269T|2001-05-10|2006-08-15|Astellas Pharma Inc|TABLETS QUICKLY CRUMPING IN THE MOUTHHOUSE AND PROCESS FOR THEIR MANUFACTURE|
    US6872405B2|2001-05-10|2005-03-29|Yamanouchi Pharmaceutical Co., Ltd.|Quick-disintegrating tablet in buccal cavity and manufacturing method thereof|
    US6656493B2|2001-07-30|2003-12-02|Wm. Wrigley Jr. Company|Edible film formulations containing maltodextrin|
    FR2831820B1|2001-11-05|2004-08-20|Ethypharm Sa|ORODISPERSIBLE TABLET HAVING HIGH HOMOGENEITY AND PREPARATION METHOD THEREOF|
    US20030206978A1|2001-11-29|2003-11-06|Bob Sherwood|Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose|
    US20040009212A1|2002-01-30|2004-01-15|Pharma Power Biotec Co. Ltd.|Mucoadhesive thermoresponsive medicament-carrier composition|
    JP4173670B2|2002-03-08|2008-10-29|旭化成ファーマ株式会社|Orally disintegrating preparation|
    WO2003087194A1|2002-04-05|2003-10-23|United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration|Polyimides from 2,3,3',4'-biphenyltetracarboxylic dianhydride and aromatic diamines|
    MXPA04010778A|2002-05-03|2005-03-07|Janssen Pharmaceutica Nv|Polymeric microemulsions.|
    US20040106663A1|2002-09-06|2004-06-03|Talley John Jeffrey|Inhibitors of fungal invasion|
    WO2004023984A2|2002-09-13|2004-03-25|Smith C Steven|Novel composition and method for treatment of upper respiratory conditions|
    JP4475233B2|2003-01-21|2010-06-09|日本新薬株式会社|Orally rapidly disintegrating tablets|
    AU2004208644B2|2003-01-31|2009-07-23|Orexo Ab|A rapid-acting pharmaceutical composition|
    US20040208833A1|2003-02-04|2004-10-21|Elan Pharma International Ltd.|Novel fluticasone formulations|
    US8012505B2|2003-02-28|2011-09-06|Alk-Abello A/S|Dosage form having a saccharide matrix|
    US20040265375A1|2003-04-16|2004-12-30|Platteeuw Johannes J.|Orally disintegrating tablets|
    US20050009848A1|2003-07-10|2005-01-13|Icn Pharmaceuticals Switzerland Ltd.|Use of antivirals against inflammatory bowel diseases|
    US7731947B2|2003-11-17|2010-06-08|Intarcia Therapeutics, Inc.|Composition and dosage form comprising an interferon particle formulation and suspending vehicle|
    BRPI0508612A|2004-03-10|2007-08-14|Schering Aktiengellschaft|compositions comprising molecularly dispersed drospirenone|
    US8545881B2|2004-04-19|2013-10-01|Eurand Pharmaceuticals, Ltd.|Orally disintegrating tablets and methods of manufacture|
    PL1634586T3|2004-09-09|2007-07-31|Laboratorio Medinfar Produtos Farm S A|Fast water-dispersible domperidone tablets|
    US20060105038A1|2004-11-12|2006-05-18|Eurand Pharmaceuticals Limited|Taste-masked pharmaceutical compositions prepared by coacervation|
    US20070020330A1|2004-11-24|2007-01-25|Medpointe Healthcare Inc.|Compositions comprising azelastine and methods of use thereof|
    US20060292099A1|2005-05-25|2006-12-28|Michael Milburn|Treatment of eye disorders with sirtuin modulators|
    US20070059361A1|2005-09-09|2007-03-15|University Of Manitoba|Fast-disintegrating epinephrine tablets for buccal or sublingual administration|
    US8497258B2|2005-11-12|2013-07-30|The Regents Of The University Of California|Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract|
    US8679545B2|2005-11-12|2014-03-25|The Regents Of The University Of California|Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract|
    US8324192B2|2005-11-12|2012-12-04|The Regents Of The University Of California|Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract|
    CN1985799B|2005-12-19|2011-11-09|量子高科（北京）研究院有限公司|Preparing process for oral disintegrated preparation|
    BRPI0620578A2|2005-12-27|2011-12-06|Jubilant Organosys Ltd|pharmaceutical composition that dissolves in the mouth and process for the preparation thereof|
    US20080260655A1|2006-11-14|2008-10-23|Dov Tamarkin|Substantially non-aqueous foamable petrolatum basedpharmaceutical and cosmetic compositions and their uses|
    EP1958613A1|2007-02-15|2008-08-20|Polichem S.A.|Dermal film-forming liquid formulations for drug release to skin|
    EP2148659A2|2007-04-13|2010-02-03|Somaxon Pharmaceuticals, Inc.|Low-dose doxepin formulations|
    US9050368B2|2007-11-13|2015-06-09|Meritage Pharma, Inc.|Corticosteroid compositions|
    US20090123551A1|2007-11-13|2009-05-14|Meritage Pharma, Inc.|Gastrointestinal delivery systems|
    US20150231156A1|2007-11-13|2015-08-20|Meritage Pharma, Inc.|Corticosteroid compositions|
    US20100216754A1|2007-11-13|2010-08-26|Meritage Pharma, Inc.|Compositions for the treatment of inflammation of the gastrointestinal tract|
    EP2211896B1|2007-11-13|2018-01-03|Meritage Pharma, Inc.|Compositions for the treatment of gastrointestinal inflammation|
    BRPI0820997A2|2007-12-10|2014-12-23|Eurand Inc|Oral disintegration tablets comprising diphenhydramine.|
    AR069875A1|2007-12-21|2010-02-24|Eurand Inc|TEMAZEPAM COMPOSITIONS FOR ORAL DISINTEGRATION TABLETS AND PREPARATION METHOD|
    JP2009173552A|2008-01-21|2009-08-06|Lion Corp|Gastrointestinal medicine|
    SE533435C2|2008-04-03|2010-09-28|Hm Power Ab|Torque transmitting arrangement at a wind turbine|
    AT498396T|2008-07-21|2011-03-15|Falk Pharma Gmbh|PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF THE UPPER DIGESTIVE STRUCTURE|
    CN102112114A|2008-08-08|2011-06-29|麦克内尔-Ppc股份有限公司|Use of sucralose as a granulating agent|
    SI2328553T1|2008-08-20|2020-10-30|The Regents Of The University Of California|Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract|
    CA2765033C|2009-06-12|2020-07-14|Meritage Pharma, Inc.|Methods for treating gastrointestinal disorders|
    PT3403654T|2009-10-01|2019-09-05|Adare Dev I L P|Orally administered corticosteroid compositions|
    US20120282335A1|2010-12-02|2012-11-08|Aptalis Pharmatech Inc.|Rapidly dispersing granules, orally disintegrating tablets and methods|
    WO2015034678A2|2013-09-06|2015-03-12|Aptalis Pharmatech, Inc.|Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis|
    LT2886108T|2013-12-23|2019-03-25|Dr. Falk Pharma Gmbh|Optimised pharmaceutical formula for the treatment of inflammatory changes of the esophagus|
    WO2015142739A1|2014-03-17|2015-09-24|Children's Hospital Medical Center|Genetic test for determining susceptibility for eosinophilic esophagitis|
    US10176301B2|2014-09-11|2019-01-08|Meritage Pharma, Inc.|Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis|
    US9980975B2|2015-01-22|2018-05-29|Ems S.A.|Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus|
    TWI728172B|2016-08-18|2021-05-21|美商愛戴爾製藥股份有限公司|Methods of treating eosinophilic esophagitis|
    CA3090832A1|2018-02-21|2019-08-29|Adare Pharmaceuticals Us, L.P.|Methods of managing eosinophilic esophagitis|
    WO2021067585A1|2019-10-01|2021-04-08|Adare Pharmaceuticals Us, L.P.|Methods of treating eosinophilic esophagitis and reducing candidiasis|EP2211896B1|2007-11-13|2018-01-03|Meritage Pharma, Inc.|Compositions for the treatment of gastrointestinal inflammation|
    US20100216754A1|2007-11-13|2010-08-26|Meritage Pharma, Inc.|Compositions for the treatment of inflammation of the gastrointestinal tract|
    US9050368B2|2007-11-13|2015-06-09|Meritage Pharma, Inc.|Corticosteroid compositions|
    CA2765033C|2009-06-12|2020-07-14|Meritage Pharma, Inc.|Methods for treating gastrointestinal disorders|
    PT3403654T|2009-10-01|2019-09-05|Adare Dev I L P|Orally administered corticosteroid compositions|
    US20120164080A1|2010-06-24|2012-06-28|Meritage Pharma, Inc.|Methods of treatment for esophageal inflammation|
    WO2012020279A1|2010-08-13|2012-02-16|Compagnie Gervais Danone|Product for the upper gastric sphere|
    US8765725B2|2012-05-08|2014-07-01|Aciex Therapeutics, Inc.|Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof|
    US9815865B2|2013-01-07|2017-11-14|Nicox Ophthalmics, Inc.|Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof|
    ES2813397T3|2012-05-08|2021-03-23|Nicox Ophthalmics Inc|Polymorphic form of fluticasone propionate|
    JP6170234B2|2013-03-15|2017-07-26|アプレシア・ファーマスーティカルズ・カンパニー|A rapidly dispersing dosage form containing levetiracetam|
    US10716802B2|2013-03-15|2020-07-21|The Brigham And Women's Hospital, Inc.|Compounds to modulate intestinal absorption of nutrients|
    US9339489B2|2013-03-15|2016-05-17|Aprecia Pharmaceuticals Company|Rapid disperse dosage form containing levetiracetam|
    GB201308933D0|2013-05-17|2013-07-03|Diurnal Ltd|Paediatric composition|
    US9078853B2|2013-06-18|2015-07-14|Cmpd Licensing, Llc|Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders|
    WO2015034678A2|2013-09-06|2015-03-12|Aptalis Pharmatech, Inc.|Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis|
    WO2015152517A1|2014-03-31|2015-10-08|세하바이오|Method for manufacturing prolamin-based oral film for protecting activity of antioxidative material|
    US9980975B2|2015-01-22|2018-05-29|Ems S.A.|Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus|
    EP3047846A1|2015-01-22|2016-07-27|Ems S.A.|Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus|
    WO2016174664A1|2015-04-29|2016-11-03|Dexcel Pharma Technologies Ltd.|Orally disintegrating compositions|
    US9877971B2|2015-06-15|2018-01-30|Banner Life Sciences Llc|Soft lozenges comprising corticosteroids|
    US9867834B2|2015-06-15|2018-01-16|Banner Life Sciences Llc|Non-systemic topical compositions comprising corticosteroids|
    EP3352738A4|2015-09-24|2019-06-05|The Brigham and Women's Hospital, Inc.|Water-activated mucoadhesive compositions to reduce intestinal absorption of nutrients|
    CN105412123B|2015-11-06|2018-03-13|山东省千佛山医院|Application of budesonide joint antifungal drug in triazole class and products thereof|
    US10076494B2|2016-06-16|2018-09-18|Dexcel Pharma Technologies Ltd.|Stable orally disintegrating pharmaceutical compositions|
    TWI728172B|2016-08-18|2021-05-21|美商愛戴爾製藥股份有限公司|Methods of treating eosinophilic esophagitis|
    US10525025B2|2016-11-17|2020-01-07|Cmpd Licensing, Llc|Compounded compositions and methods for treating pain|
    US9999604B2|2016-11-17|2018-06-19|Cmpd Licensing, Llc|Compounded solutions of diclofenac and lidocaine and methods|
    WO2019157453A1|2018-02-12|2019-08-15|Trilogy Therapeutics, Inc.|Caspofungin compositions for inhalation|
    SI25373A|2018-05-08|2018-08-31|Danijela Marković|Natural orodispersible tablet|
    WO2021067585A1|2019-10-01|2021-04-08|Adare Pharmaceuticals Us, L.P.|Methods of treating eosinophilic esophagitis and reducing candidiasis|
    KR102275997B1|2019-11-07|2021-07-13|연세대학교 산학협력단|A composition for Host-directed therapy|
    法律状态:
    2021-10-19| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2021-10-26| B25D| Requested change of name of applicant approved|Owner name: ADARE PHARMACEUTICALS, INC. (US) |
    2021-11-16| B25G| Requested change of headquarter approved|Owner name: ADARE PHARMACEUTICALS, INC. (US) |
    2021-12-28| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    优先权:
    申请号 | 申请日 | 专利标题
    US24764209P| true| 2009-10-01|2009-10-01|
    US61/247,642|2009-10-01|
    PCT/US2010/050860|WO2011041509A1|2009-10-01|2010-09-30|Orally administered corticosteroid compositions|
    [返回顶部]